Preclinical data opening new perspectives for development of lirilumab in combination to be presented at ASH

• Evidence for lirilumab single-agent activity in lymphoma
• Demonstration of enhanced efficacy of anti-CD20 antibodies when combined with lirilumab
• To be presented at ASH meeting, December 9, abstract available online now

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces that a new set of preclinical data on lirilumab will be presented in a poster at the upcoming 55th ASH Annual Meeting (December 7-10, 2013) in New Orleans, LA:

“Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies”